On Tuesday, healthcare giant Pfizer (NYSE: PFE) reported its third-quarter results, which came in far better than expected. Management has also raised its guidance for the year in light of its stellar performance. Pfizer's stock has been rallying this year, but it's still down more than 30% in five years, as investors remain cautious now that the business isn't generating huge amounts of revenue from its COVID vaccine and pill.
POLARIS INSIGHTS